# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Asthika Goonewardene maintains IGM Biosciences (NASDAQ:IGMS) with a Hold and lowers the price targ...
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0...
JP Morgan analyst Eric Joseph upgrades IGM Biosciences (NASDAQ:IGMS) from Underweight to Neutral.
Jefferies analyst Roger Song downgrades IGM Biosciences (NASDAQ:IGMS) from Buy to Hold and lowers the price target from $48 ...
Truist Securities analyst Asthika Goonewardene maintains IGM Biosciences (NASDAQ:IGMS) with a Hold and lowers the price targ...